A list of all abbreviations and terms appearing in this issue of *Therapy*.

ACCE Active supportive care ACE Active supportive care ACE ACCE Active supportive care ACCE ACCE CACCE	Α	Acute	FDPS	Finnish Diabetes Prevention	MEC	Moderately emetogenic
ACET Angiotensin-converting enzyme Event Lowering in Diabetes MPM Malignant pleural mesothelioma ADCC Antibody-dependent cytoxicity FLIE FISH Follicular lymphoma NCLWS National Cancer Institute AMI Alarine transaminase FUE Functional Living Index of Emesis NCLWS National Cancer Institute AMP Artral natriuretic peptide ARS Active supportive care GRAFT Glycinamide ribonucleotide formyl transferase NR NNn-Hodgkin lymphoma Nno-Hodgkin lymphoma ASS Black vesupportive care GFR Glomerular filtration rate NR Not reported AUC Area under the curve Hb Hb Hb Moreular filtration rate NR NCLL Not reported ABB Billocker Hb Hb Hb Hb Hongolbin QR Organic cation transporter OR Organic cation transporter OR Organic cation transporter PAR2 Protease-activated receptor-2 PhSP Protease-activated receptor-2 PhSP Protease-activated receptor-2 Protease-activated receptor-3	ACCOR			•		
ACTC Altobody-dependent cytotoxicity cytotox			FIELD			•
ADCE cytotoxicity Alanine transaminase AMI Aute myocardial infarction AMP Artial natriuretic peptide ARB ARB Angiotensin receptor blocker ASC Active supportive care ACC Area under the curve ABS BB B						
ALT Alanier transminase AMI Acute myocardial infarction AMP Atrial natriuretic peptide ARB Angiotensin receptor blocker ASC Active supportive care ASC Care active supportive filed						
AMI Acute myocardial infarction FVC Forced vital capacity NHL Non-hodgkin lymphoma Novel neurokinin 1 Not reported Forced vital capacity NHL Non-hodgkin lymphoma Novel neurokinin 1 Not reported Formyl transferase NR Not reported NRC NRC Active supportive care GR Glomerular filtration rate GRAST Active supportive care GR Glomerular filtration rate GRAST Active supportive care GR Glomerular filtration rate GRAST MRC NRC NRC NRC NRC NRC NRC NRC NRC NRC N	ADCC				NCI-WG	
AMI Acute myocardial infarction FVC Forced vital capacity NHL Non-Hodgkin lymphoma (Application) (Ap		,				
ANP ARB Atrial natriuretic peptide GARFT formyl transferase NKI novel neurokinin 1 Novel neurokinin 1 ASC Active supportive care GFR Glomerular filtration rate NSCLC Non-small-cell lung cancer ASC Active supportive care GFR Glomerular filtration rate NSCLC Organic cation transporter BAS Bile acid sequestrant HD Hemoglobin OR Overall response BB β-blocker HCP Healthcare provider PAR2 Protesse-activated receptor-2 CAD Coronary artery disease HDL-C HEC HEC Healthcare provider PAR2 Protesse-activated receptor-2 CAPP Catogroft Prevention Project HEC HEC HEC HEC HEC HEC PRPAS2 Protesse-activated receptor-2 Protesse-activated receptor-2 CCR Cardioprotective regimen HEC HEC HEC HEC Hemotherapy-induced nausea and vomiting HEC HER2 Human epidermal growth factor PVD Peripheral vascular disease CLIV Chronic kidney disease				· · · · · · · · · · · · · · · · · · ·		•
ARSE Active supportive care GFR Gomerular filtration rate NSCL Concording the formy it ransferase (ACC) Active supportive care (ACC) Active supportive (ACC) Active supp						
ASC Active supportive care AUC Area under the curve GFR Gastrointestinal Glore author flow care author the curve GFR Gastrointestinal OCT Organic cation transporter One-small-cell lung cancer BAS Bile acid sequestrant BB B β-blocker HCP Healthcare provider PAR2 Protease-activated receptor-2 Overall response PAR2 Protease-activated receptor-2 PR2 Protease-activated recepto			GARFI			
AUC Area under the curve GI Gastrointestinal OCT Organic cation transporter BAS Bile acid sequestrant HB Hemoglobin OR Overall response BBI P-blocker HCP Healthcare provider PAR2 Protease-activated receptor-2 CAD Coronary artery disease HEC High-density lipoprotein cholesterol PRS Platelet-derived growth factor receptor CCBC Calcium channel blocker HEC Highly emetogenic chemotherapy PRS Progression-free survival chemotherapy CCT Confidence interval HEC Highly emetogenic chemotherapy PR Partial responses CINV Chemotherapy-induced nausea and vomiting HER2 HIMGCR HIMGCR HER2 HIMGCR HER2 HER2 HIMGCR HER2 HER2 HER3 Recommended dietary allowance CLL Chronic kindrey disease HF HOPE HHMGCR HMGCR HGC RECIST Reclost Reclost Reclost Reclost Reclost Reclost Reclost Reclost			CED			•
BAS Bile acid sequestrant Hb Hemplobin OR Overall response BMI Boly blocker HCP Healthcare provider PAR2 Protease-activated receptor-2 CAD Coronary artery disease Captoprofil Prevention Project HEC Highly emetogenic chemotherapy PFS Progression-free survival receptor receptor Progression-free survival CCR Cardioprotective regimen HEC Highly emetogenic chemotherapy PR Progression-free survival CEP Cholesteryl ester transfer protein HEC Highly emetogenic chemotherapy PR Partial responses CED Chonic kidney disease HER2 Human epidermal growth factor receptor 2 receptor 2 PR Partial responses CLL Chronic kidney disease HMGC-GoA reductase RBC Red blood cell CLL Chronic kidney disease HMGC-GoA reductase RBC Red blood cell CLL Chronic kidney disease HOT Heart failure REC CR Corticotropin-releasing hormone HOT Heart failure REC CRF Croticotrop						
BBI B-blocker BCP HcP Healthcare provider PAR2 Protease-activated receptor 2						
BMI Body mass index FDLC High-density lipoprotein CAD Coronary artery disease CAPPP Captopril Prevention Project HEC Highly emetogenic CAPPP Captopril Prevention Project HEC Highly emetogenic PFS Progression-free survival PPMs Purine nucleoside analogs PPR Purine nucleosi		•		3		
CAPPP Captopril Prevention Project HEC Highly emetogenic chemotherapy PNAs Purine nucleoside analogs Calcium channel blocker chemotherapy PNAs Purine nucleoside analogs Cardioprotective regimen CETP Cholesteryl ester transfer protein CIT Confidence interval CINV Chemotherapy-induced nausea and vomiting HF Heart failure PNAS PVD Peripheral vascular disease PND PVD Peripheral vascular disease PND PVD Peripheral vascular disease PNAS PVD Peripheral vascular disease PVD PVD Peripheral vascular disease PVD PVD Peripheral vascular disease PVD		•				
CAPPP Captopril Prevention Project CCB Calcium channel blocker CCR Cardioprotective regimen CETP Cholesteryl ester transfer protein CI Confidence interval CINV Chemotherapy-induced nausea and vomiting CRD Chronic kidney disease CLL Chronic lymphocytic leukemia CR Complete response CTP Confesterol retament Trialists CRF Corticotropin-releasing hormone CT Computed tomography CTTC Collaborators CVD Cardiovascular disease DCCT Collaborators CVD Cardiovascular disease DCCT Diabetes Control and DCCT Diabetes Control and DCCT Diabetes Control and DDPD Delayed DHFR Dihydrofolate reductase DIAD Detection of Ischemia in DDPD Diabetes Rellfus DIAD Diabetes Rellfus DND Diabetes Prevention Program ECD Extracellular domain ECD Extracellular domain ECD Extracellular domain ECR Estmated glomerular filtration rate ECR CROMIT A RESPONSE VALIDATION CARRES (MEC Moderately emetogenic CMD Extra-pleural pneumonectomy ER ESTRO Estractage and pownth factor receptor ECRD Extra-pleural pneumonectomy ER ESTRO Estractage and sease HEC Highly emetogenic chemotherapy Chemotherapy PVD Peripheral vascular disease HEC Highly emetogenic chemotherapy PVD Peripheral vascular disease NEC Red blood cell RAS Response Evaluation Treatment Phe Heart Guitcomes Prevention RECS Red blood cell RAS Response Evaluation Criteria In Solid Tumors SERT Secrotonin reuptake transporter SERT Testenter Trialists SCC Onstipation predominant IBS T11W1 T1-weighted image T12W1 T2-weighted image T12W1 T2-wei			HDL-C		PDGFK	_
CCR Calcium channel blocker Chemotherapy PNAs Purine nucleoside analogs CCR Cardioprotective regimen HEC Highly emetogenic PR Partial responses CETP Cholesteryl ester transfer protein HERZ Human epidermal growth factor receptor 2 Quality of life CINV Chemotherapy-induced nausea and vomiting HF Heart failure RAAS Renin-angiotensin-aldosterone system CKD Chronic kidney disease HMGCCA HMG-CoA reductase RBC Red blood cell Recommended dietary allowance CR Complete response Feart Outcomes Prevention RECIST Recommended dietary allowance CRF Corticotropin-releasing hormone HD Hypertension Optimal Treatment SERT Serotonin reuptake transporter CTTC Conblesterol Treatment Trialists IBC Inflammatory breast cancer SSRI Selective serotonin reuptake transporter CVD Cardiovascular disease IBS-D Diarrhea predominant IBS SVC Slow vital capacity CVY Cyclophosphamide IBS-M Mixed pattern IBS TIWI			LIEC		DEC	•
CCTP Cholesteryl ester transfer protein CI Confidence interval CI Confidence interval CI CINV Chemotherapy-induced nausea and vomiting CI Chronic kidney disease CI CLL Chronic lymphocytic leukemia CR Complete response CT COmplete romagnaphy CT CT Complete romagnaphy CT CT Complete romagnaphy CT CT COmpleted tomography CT CT COmpleted tomography CT CT COmpleted tomography CT CT COmpleted tomography CT CT COmplete romagnaphy CT CT COmplete of the complete response CT COmpleted tomography CT CT Complete romagnaphy CT CT Complete of the complete response CT CT Complete romagnaphy CT CT CT CT Complete romagnaphy CT			HEC	• •		
CETP Cholesteryl ester transfer protein CI Confidence interval CINV Chemotherapy-induced nausea and womiting CKD Chronic kidney disease CLL Chronic lymphocytic leukemia CR Complete response CRF Corticotropin-releasing hormone CT Computed tomography CTTC Cholesterol Treatment Trialists COllaborators CVD Cardiovascular disease D Delayed D Delayed D Diabetes Control and COmplications Trial DIAD DIAD DIAD DIAD DIAD DIAD DIAD DIA			LIEC	. ,		
CINV Chemotherapy-induced nausea and womiting HF Heart failure receptor 2 RAAS Renin-angiotensin-aldosterone system CKD Chronic kidney disease HMGCR HMG-CoA reductase RBC Red blood cell RCLL Chronic lymphocytic leukemia CR Complete response Evaluation Phypertension Optimal Treatment CT Computed tomography Hp Hp Hptoglobin RECIST Response Evaluation Criteria In Solid Tumors CT Computed tomography Hp Hptoglobin SC SERI Selective serotonin reuptake transporter Scollaborators IBS Irritable bowel syndrome CVD Cardiovascular disease IBS-C Constipation predominant IBS SVC Slow vital capacity CY Cyclophosphamide IBS-D Diarrhea predominant IBS SVC Slow vital capacity CCT Diabetes Control and Complications Trial Detection of Ischemia in Asymptomatic Diabetics Asymptomatic Diabetics Algorithms and Complications Program LD Diabetes Prevention Program LD LDL-C Low-density lipoprotein Cholesterol LDL-C Low-density lipoprotein receptor Estimated glomerular filtration receptor LVH Left ventricular hypertrophy receptor End-stage renal disease MEC Moderately emetogenic HEC Moderately emetogenic HEC Stracellular and sease MEC Moderately emetogenic HEC Stracellular program LDL-Stage renal disease MEC Moderately emetogenic HEC Supportive Care in Cancer MEC Moderately emetogenic HEC Supportive Care in C			HEC			
CINV Chemotherapy-induced nausea and vomiting HF Heart failure system CKD Chronic kidney disease HMGCR HMG-CoA reductase RBC Red blood cell CLL Chronic lymphocytic leukemia CR Complete response Evaluation Evaluation RCR Corticotropin-releasing hormone CT Computed tomography HD Haptoglobin SERT Solid Tumors CTT Computed tomography HD Haptoglobin SERT Serotonin reuptake transporter CTT Collaborators IBS Inflammatory breast cancer CY Cyclophosphamide IBS-D Diarrhea predominant IBS SVC Slow vital capacity CY Cyclophosphamide IBS-D Diarrhea predominant IBS TIVNI T1-weighted image D Delayed IBS-D Diarrhea predominant IBS TIVNI T1-weighted image D Delayed IBS-D Diarrhea predominant IBS TIVNI T2-weighted image DCCT Diabetes Control and Complications Trial DHFR Dihydrofolate reductase IFG Impaired fasting glycemia Asymptomatic Diabetics IGFR-1 Insulin-like growth factor-1 Impaired glucose tolerance Interventions and Complications EDP Diabetes Prevention Program IL Intensive lifestyle Impaired fasting streep to cholesterol LDL-C Low-density lipoprotein T2D Thiazolidinedione EDIC Epidemiology of Diabetes Interventions and Complications EGFR Epidemal growth factor receptor LVH Left ventricular hypertrophy reach cancer RESD End-stage renal disease MEC Moderately emetogenic HEC Worderately emetogen			LIEDO			•
CKD Chronic kidney disease CLL Chronic kidney disease CRF Complete response CRF Complete response CRF Corticotropin-releasing hormone CT Computed tomography CTC Computed tomography CTC Cholesterol Treatment Trialists Collaborators CVD Cardiovascular disease CVC Cyclophosphamide CVC Slow vital capacity CY Slow vital capacity Cyclophosphamide Cy Slow vital capacity Cyclopho			HEKZ		-	
CKD Chronic kidney disease CLL Chronic lymphocytic leukemia CR Complete response COmplete response Corticotropin-releasing hormone CT Computed tomography CTTC Cholesterol Treatment Trialists COllaborators COID Cardiovascular disease D Delayed D Delayed D Delayed D Diabetes Control and Complications Trial DHFR Dihydrofolate reductase DHAD Detection of Ischemia in Asymptomatic Diabetics DM Diabetes mellitus	CINV		ше		NAAS	_
CLLChronic lymphocytic leukemiaHOPEHeart Outcomes PreventionRDARecommended dietary allowanceCRComplete responseEvaluationRECISTResponse Evaluation Criteria InCRFCorticotropin-releasing hormoneHOTHypertension Optimal TreatmentSolid TumorsCTTComputed tomographyHpHaptoglobinSERTSerotonin reuptake transporterCTCCholesterol Treatment TrialistsIBCInflammatory breast cancerSSRISelective serotonin reuptakeCVDCardiovascular diseaseIBS-DDiarrhea predominant IBSSVCSlow vital capacityCYCyclophosphamideIBS-DDiarrhea predominant IBSTIVIT1-weighted imageDCCTDiabetes Control and Complications TrialIDPP-1Indian Diabetes Prevention ProgramT2DMType 2 diabetes mellitusDHFRDihydrofolate reductaseIFGImpaired fasting glycemiaTPATissue plasminogen activatorDADDetection of Ischemia in Asymptomatic DiabeticsIGFR-1Insulin-like growth factor-1TRPV1Transient receptor potentialDMDiabetes mellitusIHCimmunopistochemistryTSThymidine synthaseDPPDiabetes Prevention Program EDIEpidemiology of Diabetes Interventions and Complications Interventions and Complications Intervention	CKD				DDC	-
CR Complete response CRF Corticotropin-releasing hormone CT Computed tomography CTC Cholesterol Treatment Trialists COllaborators CVD Cardiovascular disease CY Cyclophosphamide D Delayed D Delayed D Diabetes Control and Complications Trial DHFR Dihydrofolate reductase DIAD Detection of Ischemia in Asymptomatic Diabetics DM Diabetes mellitus DMD Diabetes mellitus DMD Diabetes mellitus DECD Diabetes releasing by the program ECD Extracellular domain EDIC Epidemiology of Diabetes Infer munohistochemistry Interventions and Complications EGFR Epidemiology of Diabetes Infer mAbs MASCC Multinational Association of Supportive Care in Cancer ESRD End-stage renal disease Evaluation Hypertension Optimal Treatment Solid Tumors SCRT Serotonin reuptake transporter SSRI Selective serotonin reuptake inhibitor SSRI Selective serotonin reuptake inhibitor SCRT Serotonin reuptake inhibitor SSRI Selective serotonin reuptake inhibitor SCRT Selective serotonin reuptake inhibitor SCRD Ser						
CRF Corticotropin-releasing hormone CT Computed tomography Hp Haptoglobin SERT Serotonin reuptake transporter CTC Cholesterol Treatment Trialists IBC Inflammatory breast cancer Collaborators IBS Irritable bowel syndrome Inhibitor SSRT Serotonin reuptake transporter SSRI Selective serotonin reuptake inhibitor SSRT Serotonin reuptake transporter SSRI Selective serotonin reuptake inhibitor SSRT Serotonin reuptake transporter SSRT Serotonin reuptake transporter SSRT Serotonin reuptake transporter SSRT Serotonin reuptake inhibitor SSRT SERT Serotonin reuptake inhibitor SSRT SERT Serotonin reuptake inhibitor SSRT SSRT inhibitor SSRT i			HOLL			•
CTT Computed tomography			нот		ILCIDI	
CTTC Cholesterol Treatment Trialists Collaborators IBS Irritable bowel syndrome CVD Cardiovascular disease IBS-D Constipation predominant IBS SVC Slow vital capacity CY Cyclophosphamide IBS-D Diarrhea predominant IBS T1WI T1-weighted image D Delayed IBS-M Mixed pattern IBS T2DM Type 2 diabetes mellitus DCCT Diabetes Control and Complications Trial Program TG Triglyceride DHFR Dihydrofolate reductase IFG Impaired fasting glycemia Asymptomatic Diabetics IGFR-1 Insulin-like growth factor-1 IRPV1 Transient receptor potential vanilloid 1 DM Diabetes mellitus IHC Immunoglobulin TPH Tryptophan hydroxylase Vanilloid 1 DM Diabetes Prevention Program IL Intensive lifestyle TTP Time-to-progression ECD Extracellular domain LDL-C Low-density lipoprotein Cholesterol UKPDS UK Prospective Diabetes Study Interventions and Complications IEFE Losartan Intervention for receptor Estimated glomerular filtration rate MASCC Multinational Association of Supportive Care in Cancer ESRD End-stage renal disease MEC Moderately emetogenic INFO MBC Metastatic breast cancer ESRD End-stage renal disease MEC Moderately emetogenic INFO Diabeta filtration Supportive Care in Cancer ESRD End-stage renal disease MEC Moderately emetogenic INFO Diabeta filtration in the program of the					SERT	
Collaborators IBS Irritable bowel syndrome inhibitor CVD Cardiovascular disease IBS-C Constipation predominant IBS SVC Slow vital capacity CY Cyclophosphamide IBS-M Mixed pattern IBS T1WI T1-weighted image D Delayed IBS-M Mixed pattern IBS T2DM Type 2 diabetes mellitus DCCT Diabetes Control and Complications Trial IPP-1 Indian Diabetes Prevention Program TG Triglyceride DHFR Dihydrofolate reductase IFG Impaired fasting glycemia TPA Tissue plasminogen activator DIAD Detection of Ischemia in Ig Immunoglobulin TPH Tryptophan hydroxylase Asymptomatic Diabetics IGFR-1 Insulin-like growth factor-1 TRPV1 Transient receptor potential vanilloid 1 DKD Diabetes kidney disease IGT Impaired glucose tolerance DPH Diabetes Prevention Program IL Intensive lifestyle TTP Time-to-progression ECD Extracellular domain LDL-C Low-density lipoprotein TZD Thiazolidinedione EDIC Epidemiology of Diabetes Intervention for Epidemial growth factor receptor LVH Left ventricular hypertrophy VEGF Vascular endothelial growth factor receptor Extra-pleural pneumonectomy ER Estrogen receptor MBC Metastatic breast cancer ESRD End-stage renal disease MEC Moderately emetogenic				. •		·
CVD Cardiovascular disease IBS-C Constipation predominant IBS SVC Slow vital capacity CYC (yclophosphamide IBS-D Diarrhea predominant IBS T1WI T1-weighted image D Delayed IBS-M Mixed pattern IBS T2DM Type 2 diabetes mellitus DCCT Diabetes Control and Complications Trial IDPP-1 Indian Diabetes Prevention Complications Trial Program TG Triglyceride DHFR Dihydrofolate reductase IFG Impaired fasting glycemia TPA Tissue plasminogen activator DIAD Detection of Ischemia in Ig Immunoglobulin TPH Tryptophan hydroxylase Asymptomatic Diabetics IGFR-1 Insulin-like growth factor-1 TRPV1 Transient receptor potential vanilloid 1 DM Diabetes mellitus IHC immunohistochemistry TS Thymidine synthase DPP Diabetes Prevention Program IL Intensive lifestyle TTP Time-to-progression ECD Extracellular domain LDL-C Low-density lipoprotein Cholesterol UKPDS UK Prospective Diabetes Study Interventions and Complications EGFR Epidermal growth factor Endpoint Reduction PEOP Point Reduction Pattern of Endpoint Reduction Pattern of Endpoint Reduction Pattern of Endpoint Reduction Pattern of Endpoint Reduction Pattern of Supportive Care in Cancer Pattern of Supportive Care in Cancer ESRD End-stage renal disease MEC Moderately emetogenic EVICTOR Slow vital capacity T1W T1-weighted image T2DM Type 2 diabetes mellitus T2DW T2-weighted image T2DM Type 2 diabetes mellitus T2DW T2-weighted image T2DM Type 1 diabetes Triglyceride TPA Tissue plasminogen activator TRPV1 Transient receptor potential vanilloid 1 TPA Tissue plasminogen activator TRPV1 Transient receptor potential vanilloid 1 TPH Tryptophan hydroxylase TRPV1 Transient receptor potential vanilloid 1 TPH Tryptophan hydroxylase TRPV1 Transient receptor potential vanilloid 1 TPH Tryptophan hydroxylase TRPV1 Transient receptor potential vanilloid 1 TPH Tryptophan hydroxylase TRPV1 Transient receptor potential vanilloid 1 TPH Tryptophan hydroxylase TRPV1 Transient receptor potential vanilloid 1 TPH Tryptophan hydroxylase TRPV1 Transient receptor potential vanilloid 1 TRPV1 Transient receptor pote	CITC				33111	•
CY Cyclophosphamide IBS-D Diarrhea predominant IBS T1WI T1-weighted image D Delayed IBS-M Mixed pattern IBS T2DM Type 2 diabetes mellitus DCCT Diabetes Control and IDPP-1 Indian Diabetes Prevention Complications Trial Program TG Triglyceride DHFR Dihydrofolate reductase IFG Impaired fasting glycemia DIAD Detection of Ischemia in Ig Immunoglobulin TPH Tryptophan hydroxylase Asymptomatic Diabetics IGFR-1 Insulin-like growth factor-1 TRPV1 Transient receptor potential vanilloid 1 DKD Diabetes kidney disease IGT Impaired glucose tolerance DM Diabetes mellitus IHC immunohistochemistry TS Thymidine synthase DPP Diabetes Prevention Program IL Intensive lifestyle TTP Time-to-progression EDIC Epidemiology of Diabetes Interventions and Complications IFE Losartan Intervention for Endpoint Reduction Program IVH Left ventricular hypertrophy rate Program IVH Supportive Care in Cancer Supportive	CVD				SVC	
D Delayed IBS-M Mixed pattern IBS T2DM Type 2 diabetes mellitus DCCT Diabetes Control and Complications Trial Program TG Triglyceride DHFR Dihydrofolate reductase IFG Impaired fasting glycemia TPA Tissue plasminogen activator DIAD Detection of Ischemia in Ig Immunoglobulin Asymptomatic Diabetics IGFR-1 Insulin-like growth factor-1 TRPV1 Transient receptor potential DKD Diabetic kidney disease IGT Impaired glucose tolerance IDM Diabetes mellitus IHC immunohistochemistry ITPM Tryptophan hydroxylase vanilloid 1 DKD Diabetes mellitus IHC immunohistochemistry TS Thymidine synthase ILL Intensive lifestyle TTP Time-to-progression TED Extracellular domain LDL-C Low-density lipoprotein cholesterol UKPDS UK Prospective Diabetes Study Interventions and Complications ILFE Losartan Intervention for Edfermal growth factor receptor Estimated glomerular filtration rate MASCC Multinational Association of rate Estrogen receptor MBC Metastatic breast cancer ESRD End-stage renal disease MEC Moderately emetogenic						
DCCT Diabetes Control and Complications Trial Program TG Triglyceride DHFR Dihydrofolate reductase IFG Impaired fasting glycemia TPA Tissue plasminogen activator DIAD Detection of Ischemia in Ig Immunoglobulin TPH Tryptophan hydroxylase Asymptomatic Diabetics IGFR-1 Insulin-like growth factor-1 DKD Diabetic kidney disease IGT Impaired glucose tolerance DM Diabetes mellitus IHC immunohistochemistry TS Thymidine synthase DPP Diabetes Prevention Program IL Intensive lifestyle TTP Time-to-progression ECD Extracellular domain LDL-C Low-density lipoprotein Cholesterol UKPDS UK Prospective Diabetes Study Interventions and Complications EGFR Epidermal growth factor receptor Estimated glomerular filtration rate MASCC Multinational Association of rate Estrogen receptor MBC Metastatic breast cancer ESRD End-stage renal disease MEC Moderately emetogenic IFG Impaired fasting glycemia TPA Tissue plasminogen activator TPA Tissue plasminogen activator ITPH Tryptophan hydroxylase TPA Tissue plasminogen activator TPA						
Complications Trial Program TG Triglyceride DHFR Dihydrofolate reductase IFG Impaired fasting glycemia TPA Tissue plasminogen activator DIAD Detection of Ischemia in Ig Immunoglobulin TPH Tryptophan hydroxylase IGFR-1 Insulin-like growth factor-1 TRPV1 Transient receptor potential vanilloid 1 DKD Diabetic kidney disease IGT Impaired glucose tolerance DM Diabetes mellitus IHC immunohistochemistry TS Thymidine synthase DPP Diabetes Prevention Program IL Intensive lifestyle TTP Time-to-progression ECD Extracellular domain LDL-C Low-density lipoprotein TZD Thiazolidinedione Cholesterol UKPDS UK Prospective Diabetes Study Interventions and Complications ILFE Losartan Intervention for Endpoint Reduction VADT Veterans Affairs Diabetes Trial receptor Estimated glomerular filtration rate MASCC Multinational Association of Supportive Care in Cancer ESRD End-stage renal disease MEC Moderately emetogenic				•		
DHFR Dihydrofolate reductase IFG Impaired fasting glycemia TPA Tissue plasminogen activator DIAD Detection of Ischemia in Asymptomatic Diabetics IGFR-1 Insulin-like growth factor-1 TRPV1 Transient receptor potential vanilloid 1 DKD Diabetic kidney disease IGT Impaired glucose tolerance DM Diabetes mellitus IHC immunohistochemistry TS Thymidine synthase DPP Diabetes Prevention Program IL Intensive lifestyle TTP Time-to-progression ECD Extracellular domain LDL-C Low-density lipoprotein Cholesterol UKPDS UK Prospective Diabetes Study Interventions and Complications IIFE Losartan Intervention for Endpoint Reduction receptor Estimated glomerular filtration rate MASCC Multinational Association of Supportive Care in Cancer ESRD End-stage renal disease MEC Moderately emetogenic	200.					
DIAD Detection of Ischemia in Asymptomatic Diabetics IGFR-1 Insulin-like growth factor-1 TRPV1 Transient receptor potential vanilloid 1 DKD Diabetic kidney disease IGT Impaired glucose tolerance DM Diabetes mellitus IHC immunohistochemistry TS Thymidine synthase DPP Diabetes Prevention Program IL Intensive lifestyle TTP Time-to-progression ECD Extracellular domain LDL-C Low-density lipoprotein Cholesterol UKPDS UK Prospective Diabetes Study Interventions and Complications LIFE Losartan Intervention for Epidermal growth factor receptor LVH Left ventricular hypertrophy eGFR Estimated glomerular filtration rate MASCC Multinational Association of EPP Extra-pleural pneumonectomy ER Estrogen receptor MBC Metastatic breast cancer ESRD End-stage renal disease MEC Moderately emetogenic	DHFR		IFG	_		
Asymptomatic Diabetics DKD Diabetic kidney disease DM Diabetes mellitus DPP Diabetes Prevention Program ECD Extracellular domain EDIC Epidemiology of Diabetes Interventions and Complications EGFR Epidermal growth factor receptor eGFR Estimated glomerular filtration rate EPP Extra-pleural pneumonectomy ER Estrogen receptor END Extracellular domain EIL Intensive lifestyle IIL Intensive lifestyle TTP Time-to-progression TZD Thiazolidinedione UKPDS UK Prospective Diabetes Study UKPDS UK Prospective Diabetes Study ULN Upper limit normal VADT Veterans Affairs Diabetes Trial Factor MASCC Multinational Association of Supportive Care in Cancer Factor MASCC Metastatic breast cancer ESRD End-stage renal disease MEC Moderately emetogenic						
DKD Diabetic kidney disease IGT Impaired glucose tolerance vanilloid 1 DM Diabetes mellitus IHC immunohistochemistry TS Thymidine synthase DPP Diabetes Prevention Program IL Intensive lifestyle TTP Time-to-progression ECD Extracellular domain LDL-C Low-density lipoprotein TZD Thiazolidinedione EDIC Epidemiology of Diabetes cholesterol UKPDS UK Prospective Diabetes Study Interventions and Complications EGFR Epidermal growth factor receptor EST Estimated glomerular filtration rate EST Estrogen receptor EST Estrogen receptor MBC Metastatic breast cancer ESRD End-stage renal disease MEC Moderately emetogenic Vanilloid 1 Impaired glucose tolerance vanilloid 1 Impaired glucose tolerance vanilloid 1 TS Thymidine synthase TTP Time-to-progression TZD Thiazolidinedione UKPDS UK Prospective Diabetes Study UV Upper limit normal VADT Veterans Affairs Diabetes Trial vanility vanilit		Asymptomatic Diabetics			TRPV1	
DM Diabetes mellitus IHC immunohistochemistry TS Thymidine synthase DPP Diabetes Prevention Program IL Intensive lifestyle TTP Time-to-progression ECD Extracellular domain LDL-C Low-density lipoprotein TZD Thiazolidinedione EDIC Epidemiology of Diabetes Cholesterol UKPDS UK Prospective Diabetes Study Interventions and Complications LIFE Losartan Intervention for Endpoint Reduction VADT Veterans Affairs Diabetes Trial receptor Estimated glomerular filtration rate ESTRO End-stage renal disease MEC Moderately emetogenic IHC immunohistochemistry TS Thymidine synthase TTP Time-to-progression TZD Thiazolidinedione UKPDS UK Prospective Diabetes Study ULN Upper limit normal VADT Veterans Affairs Diabetes Trial vector valuation factor VEGF Vascular endothelial growth factor Factor VLCD Very low calorie diet VLCD Very low calorie diet Supportive Care in Cancer ESRD End-stage renal disease MEC Moderately emetogenic	DKD		IGT			
DPP Diabetes Prevention Program IL Intensive lifestyle TTP Time-to-progression ECD Extracellular domain LDL-C Low-density lipoprotein TZD Thiazolidinedione EDIC Epidemiology of Diabetes Cholesterol UKPDS UK Prospective Diabetes Study Interventions and Complications LIFE Losartan Intervention for Endpoint Reduction VADT Veterans Affairs Diabetes Trial receptor Estimated glomerular filtration rate EMASCC Multinational Association of EPP Extra-pleural pneumonectomy ER Estrogen receptor MBC Metastatic breast cancer ESRD End-stage renal disease MEC Moderately emetogenic	DM		IHC		TS	Thymidine synthase
ECD Extracellular domain LDL-C Low-density lipoprotein TZD Thiazolidinedione EDIC Epidemiology of Diabetes Interventions and Complications LIFE Losartan Intervention for EGFR Epidermal growth factor receptor LVH Left ventricular hypertrophy eGFR Estimated glomerular filtration rate EMP Extra-pleural pneumonectomy ER Estrogen receptor MBC Metastatic breast cancer ESRD End-stage renal disease MEC MILT METALOR ME	DPP	Diabetes Prevention Program	IL		TTP	
Interventions and Complications EGFR Epidermal growth factor receptor ESFRD End-stage renal disease LIFE Losartan Intervention for Endpoint Reduction VADT Veterans Affairs Diabetes Trial VADT VETER VADT VADT VETER VADT VADT VADT VETER VADT VADT VADT VADT VADT VATT VATT VATT	ECD	Extracellular domain	LDL-C	Low-density lipoprotein	TZD	Thiazolidinedione
EGFR Epidermal growth factor receptor LVH Left ventricular hypertrophy eGFR Estimated glomerular filtration rate MASCC Multinational Association of EPP Extra-pleural pneumonectomy ER Estrogen receptor MBC Metastatic breast cancer ESRD End-stage renal disease MEC MEC MIDIO METASTA STATE S	EDIC	Epidemiology of Diabetes		cholesterol	UKPDS	UK Prospective Diabetes Study
receptor		Interventions and Complications	LIFE	Losartan Intervention for	ULN	Upper limit normal
eGFR Estimated glomerular filtration mAbs Monoclonal antibodies factor rate MASCC Multinational Association of VLCD Very low calorie diet EPP Extra-pleural pneumonectomy ER Estrogen receptor MBC Metastatic breast cancer ESRD End-stage renal disease MEC Moderately emetogenic	EGFR	Epidermal growth factor		Endpoint Reduction	VADT	Veterans Affairs Diabetes Trial
rate MASCC Multinational Association of VLCD Very low calorie diet EPP Extra-pleural pneumonectomy ER Estrogen receptor MBC Metastatic breast cancer ESRD End-stage renal disease MEC Moderately emetogenic			LVH	Left ventricular hypertrophy	VEGF	Vascular endothelial growth
EPP Extra-pleural pneumonectomy Supportive Care in Cancer ER Estrogen receptor MBC Metastatic breast cancer ESRD End-stage renal disease MEC Moderately emetogenic	eGFR	Estimated glomerular filtration	mAbs			
ER Estrogen receptor MBC Metastatic breast cancer ESRD End-stage renal disease MEC Moderately emetogenic		rate	MASCC	Multinational Association of	VLCD	Very low calorie diet
ESRD End-stage renal disease MEC Moderately emetogenic						
FA Fludarabine chemotherap			MEC			
	FA	Fludarabine		chemotherap		